Horizon Therapeutics (HZNP) Tops Q1 EPS by 18c, Raises FY Rev. Guidance
Get Alerts HZNP Hot Sheet
Join SI Premium – FREE
Horizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $0.40, $0.18 better than the analyst estimate of $0.22. Revenue for the quarter came in at $355.9 million versus the consensus estimate of $287.88 million.
GUIDANCE:
Horizon Therapeutics sees FY2020 revenue of $1.4-1.45 billion, versus the consensus of $1.35 billion.
- The Company now expects full‐year 2020 net sales to range between $1.40 billion and $1.45 billion, an increase from the previous range of $1.40 billion to $1.42 billion, reflecting the significant increase in full-year TEPEZZA net sales guidance, offset by the current estimated impact of COVID-19 on its medicines. The Company now expects TEPEZZA full-year net sales of greater than $200 million, compared to the previous guidance of $30 million to $40 million. Full-year 2020 adjusted EBITDA is now expected to range between $450 million and $500 million, revised from the previous guidance range of $485 million to $500 million and reflects increased investment in TEPEZZA to support higher-than-expected demand, new TEPEZZA clinical programs and HZN-825. The updated guidance assumes that healthcare activity begins to return in the second half of 2020.
For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
- Ford (F) earnings beat estimates in Q1, revenue falls short; stock up
- FS Bancorp (FSBW) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!